Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Something to note

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Aug 10, 2022 11:40am

96 Views

Post# 34884958

RE:RE:RE:RE:Something to note

The last study for ibalizumab was a phase III, even though it had only 40 patients in it.

https://www.nejm.org/doi/full/10.1056/nejmoa1711460

SPCEO1 wrote: Trogarzo was a drug the FDA loved and so it had a lot of shortcuts ont he way to approval. I believe the FDA actually contributed $500,000 to Taimed to help develop the drug. Small studies, no phase III required were other benefits along with the lack of a comparison arm to their trials. This study looks to fix that last one if I am reading it right.

PWIB123 wrote: Sounds promising, but am I reading this that they effectively took another short-cut?